Waystar Considers Sale Amid Falling Market Value, Sources Reveal

Healthcare software provider Waystar is reportedly exploring strategic options, including a potential sale, just two years after going public. The move comes as the company's market value has plummeted by 24% this year amid a general downturn in the software sector. According to seven sources familiar with the situation, Waystar has engaged investment bank Evercore to assist with the process, which remains in its preliminary stages.

Potential Return to Private Ownership

Waystar, headquartered in Lehi, Utah, and Louisville, Kentucky, has not confirmed any specific course of action, and the possibility of a sale remains uncertain, the sources noted. The company, which specializes in software to automate administrative tasks for hospitals and physicians, initially positioned itself to achieve higher valuations typical of tech companies. This strategic positioning aimed to differentiate it from healthcare services firms that rely more on manual labor.

Despite these efforts, Waystar's stock has faced significant pressure, dropping from a peak of $45 in 2025 to its current valuation of approximately $4.8 billion. Concerns about the potential impact of artificial intelligence advancements on software companies have contributed to investor apprehensions, as highlighted in a July report by Morgan Stanley analysts.

Corporate History and Stakeholders

Waystar was created in 2017 through the merger of healthcare revenue management companies Zirmed and Navicure. Major stakeholders include EQT, the Canada Pension Plan Investment Board (CPPIB), and Bain Capital, which took the company public in 2024. EQT holds a 13% stake, making it the largest shareholder, followed by CPPIB with 10% and BlackRock Institutional Trust Company with 8%, according to LSEG data.

Neither EQT nor CPPIB has commented on the potential sale, and BlackRock has also declined to comment. The exploration of a sale could test the waters for investor interest in software businesses, which have been experiencing a broader selloff.

Waystar's Strategic Focus

Waystar's emphasis on technology-driven solutions was intended to win favor among investors who value innovation and automation. By automating healthcare administrative functions, the company sought to reduce reliance on manual processes. This strategy initially resonated with the market, with shares rising from $20 at the IPO to $45 before the recent downturn.

The ongoing evaluation of strategic options, including a potential sale, suggests that Waystar is responding to the shifting dynamics in the software and healthcare sectors. As the process unfolds, the outcome will depend on the broader market's appetite for software investments and the company's ability to navigate the challenges posed by technological advancements.